GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (NYSE:RMD) » Definitions » Earnings per Share (Diluted)

ResMed (ResMed) Earnings per Share (Diluted)

: $6.05 (TTM As of Dec. 2023)
View and export this data going back to 1995. Start your Free Trial

ResMed's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $1.42. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $6.05.

ResMed's EPS (Basic) for the three months ended in Dec. 2023 was $1.42. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $6.05.

ResMed's EPS without NRI for the three months ended in Dec. 2023 was $1.88. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $6.80.

During the past 12 months, ResMed's average EPS without NRIGrowth Rate was 13.70% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 14.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 23.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was 12.20% per year.

During the past 13 years, ResMed's highest 3-Year average EPS without NRI Growth Rate was 84.40% per year. The lowest was -2.40% per year. And the median was 21.60% per year.


ResMed Earnings per Share (Diluted) Historical Data

The historical data trend for ResMed's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ResMed Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Earnings per Share (Diluted)
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.80 4.27 3.24 5.30 6.09

ResMed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings per Share (Diluted) Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.53 1.58 1.56 1.49 1.42

Competitive Comparison

For the Medical Instruments & Supplies subindustry, ResMed's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed PE Ratio Distribution

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's PE Ratio distribution charts can be found below:

* The bar in red indicates where ResMed's PE Ratio falls into.



ResMed Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

ResMed's Earnings Per Share (Diluted) for the fiscal year that ended in Jun. 2023 is calculated as

Diluted Earnings Per Share (A: Jun. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(897.556-0)/147.455
=6.09

ResMed's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(208.8-0)/147.545
=1.42

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


ResMed  (NYSE:RMD) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


ResMed Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of ResMed's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


ResMed (ResMed) Business Description

Address
9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Executives
Brett Sandercock officer: Chief Financial Officer 17 GUINEVIERE COURT, CASTLE HILL, NEW SOUTH WALES C3 2154
Michael J. Farrell officer: Chief Executive Officer C/O REMED INC, 9001 SPECTRUM CTR. BLVD., SAN DIEGO, CA 92123
Michael J Rider officer: Global General Counsel 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Robert Andrew Douglas officer: President and COO 21 ATTUNGA ROAD, NEWPORT, NEW SOUTH WALES C3 2106
Kaushik Ghoshal officer: President, SaaS Business 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
David Pendarvis officer: Chief Administration Officer REDMED INC, 14040 DANLELSON ST, POWAY CA 92064
Karen Drexler director C/O DIADEXUS, INC., 343 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Justin Leong officer: President, Asia and LATAM C/O RESMED INC, 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Desney Tan director 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
John Hernandez director 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Lucile Blaise officer: President, Sleep & RC Business RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
James Hollingshead officer: President, Sleep Business C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Carol Burt director C/O WELLCARE HEALTH PLANS, INC., 8725 HENDERSON ROAD, TAMPA FL 33634
Resmed Inc director 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123

ResMed (ResMed) Headlines

From GuruFocus

Q3 2022 Resmed Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Resmed Inc to Acquire Medifox Dan GmbH Call Transcript

By GuruFocus Research 01-23-2024

Q1 2022 Resmed Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Resmed Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2022 Resmed Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Resmed Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 01-23-2024